Firoz Ahmad

Firoz Ahmad

Auto-generated profile, based on publicly available information

Firoz Ahmad

SRL Limited

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2014 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
SBSwati Bisht
Swati Bisht
FAFiroz Ahmad
Firoz Ahmad
SSSatyakam Sawaimoon
Satyakam Sawaimoon
SBSimi Bhatia
Simi Bhatia
BDBibhu Ranjan Das
Bibhu Ranjan Das

1 February 2014 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
FAFiroz Ahmad
Firoz Ahmad
RMRupali Mohota
Rupali Mohota
SSSavita Sanap
Savita Sanap
SMSwarna Mandava
Swarna Mandava
BDBibhu Ranjan Das
Bibhu Ranjan Das
Molecular Evaluation of DNMT3A and IDH1/2 Gene Mutation: Frequency, Distribution Pattern and Associations with Additional Molecular Markers in Normal Karyotype Indian Acute Myeloid Leukemia Patients Molecular markers;DNMT3A;IDH;normal karyotype AML;risk stratification; Mutations in the DNMT3A and IDH genes represent the most common genetic alteration after FLT3/NPM1 in acute myeloid leukemia (AML). We here analyzed the frequency and distribution pattern of DNMT3A and IDH mutations and their associations with other molecular markers in normal karyotype AML patients. Fortyfive patients were screened for mutations in DNMT3A (R882), IDH1 (R132) and IDH2 (R140 and R172) genes by direct sequencing. Of the 45 patients screened, DNMT3A and IDH mutations were observed in 6 (13.3%) and 7 (15.4%), respectively. Patients with isolated DNMT3A mutations were seen in 4 cases (9%), isolated IDH mutations in 5 (11.1%), while interestingly, two cases showed both DNMT3A and IDH mutations (4.3%). Nucleotide sequencing of DNMT3A revealed missense mutations (R882H and R882C), while that of IDH revealed R172K, R140Q, R132H and R132S. Both DNMT3A and IDH mutations were observed only in adults, with a higher frequency in males. DNMT3A and IDH mutations were significantly associated with NPM1, while trends towards higher coexistence with FLT3 mutations were observed. This is the first study to evaluate DNMT3A/IDH mutations in Indian patients. Significant associations among the various molecular markers was observed, that highlights cooperation between them and possible roles in improved risk stratification.


9 June 2016 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
FAFiroz Ahmad
Firoz Ahmad
ABAnuya Badwe
Anuya Badwe
GVGeeta Verma
Geeta Verma
SBSimi Bhatia
Simi Bhatia
BDBibhu Ranjan Das
Bibhu Ranjan Das

8 December 2009 in Cancer Investigation
Verified
Journal Article
Closed access
PDF file
FAFiroz Ahmad
Firoz Ahmad
SMSwarna Mandava
Swarna Mandava
BDBibhu Ranjan Das
Bibhu Ranjan Das
Mutation of the FMS-like tyrosine kinase 3 (FLT3) gene in Indian population remains unclear till date. Here, we found FLT3-ITD mutations in 19.1%, FLT3-Asp835 mutations in 4.7%, and dual mutations in 4.2%, accounting for overall mutation in 28% of acute myeloid leukemia (AML) patients. FLT3 mutation was more prevalent in APL than non-APL patients (32.2% vs 26.3%), adults tend to show higher incidence than children (30.6% vs 18.2%, p =.1), and were significantly associated with normal karyotype, high WBCs, with no specific distribution in FAB subtypes. Notably, FLT3 mutation was present in 50% of patients with NPM1-Mt, when compared to only 22.6% of patients with NPM1-wt (p <.001). Sequence analyses of internal tandem duplications (ITDs) revealed that duplications were mostly restricted to JM domain (3 to 165 nucleotides). Interestingly, 92.3% cases showed duplication of at least one amino acid (AA) within the stretch Y589 to K602 that includes the two SH2-binding motifs. Analysis of frequency of single AA in the duplicated region revealed that E598 was the most frequently duplicated single AA in 72%, followed by R595 (69.2%), and Y599 (66.7%). Finally, three types of point mutations were identified, including D835Y, D835H, and D835A.

31 December 2013 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
BDBibhu Ranjan Das
Bibhu Ranjan Das
RTRajiv Tangri
Rajiv Tangri
FAFiroz Ahmad
Firoz Ahmad
ARArnab Roy
Arnab Roy
KPKamlakar Patole
Kamlakar Patole
Molecular Investigation of Isocitrate Dehydrogenase Gene (IDH) Mutations in Gliomas: First Report of IDH2 Mutations in Indian Patients Glioma;IDH1 mutation;IDH2 mutation;sequencing;India; Recent genome wide sequencing has identified mutations in IDH1/IDH2 predominantly in grade II-III gliomas and secondary glioblastomas which are associated with favorable clinical outcome. These mutations have become molecular markers of significant diagnostic and prognostic relevance in the assessment of human gliomas. In the current study we evaluated IDH1 (R132) and IDH2 (R172) in 32 gliomas of various grades and tumor subtypes. Sequencing analysis revealed R132H mutations in 18.7% tumors, while none of the cases showed IDH2 (R172) mutations. The frequency of IDH1 mutations was higher in females (21.4%) than males (11.1%), and it was significantly higher in younger patients. Histological analyses demonstrated presence of necrosis and micro vascular proliferation in 69% and 75% respectively. Interestingly, IDH1 mutations were predominantly present in non-necrotic tumors as well as in cases showing microvascular proliferation. Of the six IDH1 positive cases, three were glioblastomas (IV), and one each were anaplastic oligoastrocytoma (III), anaplastic oligodendroglioma III (n=1) and diffuse astrocytoma. In conclusion, IDH1 mutations are quite frequent in Indian glioma patients while IDH2 mutations are not observed. Since IDH mutations are associated with good prognosis, their use in routine clinical practice will enable better risk stratification and management of glioma patients.